AstraZeneca ends contract sales agreement with PDI

Share this article:
Contract sales-force provider PDI said that its fee-for-service agreements with AstraZeneca would be terminated effective April 30. The termination affects approximately 800 field representatives. The revenue impact is projected to be approximately $65 million to $70 million in 2006, PDI said. “We have worked with AstraZeneca for over 12 years and look forward to creating future business opportunities with them. We are vigorously exploring potential opportunities to redeploy these high performing sales teams,” said PDI’s president Steven Budd in a statement.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.